Immune Responses to BCG Vaccination in Malawi and the UK

BCG vaccination has been found to provide greater protection against TB in the UK than in Malawi. This study compares immune responses in BCG-vaccinated and unvaccinated teenagers and young adults in Malawi and in the UK.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Immunity, Cellular Hypersensitivity Hypersensitivity, Delayed Type Immune System Diseases

Age range

12 year–25 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Karonga Prevention Study, Chilumba, Karonga District, Malawi

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

BCG unvaccinated
HIV negative
Not pregnant
Informed Consent

Exclusion criteria

HIV positive
Pregnant
Seriously ill

Treatment and study plan

BCG

Biological

Primary outcomes

Delayed-type hypersensitivity
cytokine responses (eg IFNg) to mycobacterial antigens

Secondary outcomes

scar size

Sponsors and collaborators

Lead sponsor

London School of Hygiene and Tropical Medicine

Other

Registry information

Important dates

First posted: Oct 19, 2005
Registry last updated: Dec 15, 2005

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed